Biomarkers in IgA nephropathy

Biomarkers in Medicine

Volumn 8, Issue 10, 2014, Pages 1263-1277

  Hwang, Vicki J ^a,b   Ulu, Arzu ^a   Van Hoorebeke, Justin ^a,b   Weiss, Robert H ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

biofluid; glomerulonephritis; glycomics; IgA nephropathy; predictive biomarker; prognostic biomarker; tissue

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 1 MICROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CERULOPLASMIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4A; GAMMA INTERFERON; HEMOPEXIN; IMMUNOGLOBULIN A1; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; MANNOSE BINDING LECTIN; MICRORNA; MICRORNA 148B; MICRORNA 188 5P; MICRORNA 200A; MICRORNA 223; MICRORNA 361 3P; MICRORNA 429; MICRORNA 886; MONOCYTE CHEMOTACTIC PROTEIN 1; STEROID; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D BINDING PROTEIN; PROTEIN;

ANTIGEN ANTIBODY COMPLEX; CHRONIC KIDNEY DISEASE; COMPLEMENT BLOOD LEVEL; COMPLEMENT SYSTEM; DISEASE COURSE; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GLOMERULUS BASEMENT MEMBRANE; HEMATURIA; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN DEPOSITION; INFLAMMATION; KIDNEY BIOPSY; MESANGIUM; NONHUMAN; PATHOPHYSIOLOGY; PODOCYTE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REVIEW; URINALYSIS; ANIMAL; GENETICS; GLOMERULONEPHRITIS, IGA; METABOLISM;

ANIMALS; BIOLOGICAL MARKERS; GLOMERULONEPHRITIS, IGA; HUMANS; MICRORNAS; PROTEINS;

EID: 84919789819     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.92     Document Type: Review

References (82)

1. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am. J. Kidney Dis. 36(2), 227-237 (2000
2. Chauveau D, Droz D. Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib. Nephrol. 104, 1-5 (1993
3. Szeto CC, Lai FM, To KF., et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am. J. Med. 110(6), 434-437 (2001
4. Shen P, He L, Li Y, Wang Y, Chan M. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron. Clin. Pract. 106(4), c157-c161 (2007
5. Imai H, Miura N. A treatment dilemma in adult immunoglobulin A nephropathy: what is the appropriate target, preservation of kidney function or induction of clinical remission?. Clin. Exp. Nephrol. 16(2), 195-201 (2012
6. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J. Nephrol. 18(5), 503-512 (2005
7. Suzuki K, Honda K, Tanabe K., et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int. 63(6), 2286-2294 (2003
8. Suzuki H, Fan R, Zhang Z., et al. Aberrantly glycosylated IgA1 in iga nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Invest. 119(6), 1668-1677 (2009
9. Novak J, Julian BA, Tomana M, Mestecky J. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin. Nephrol. 28(1), 78-87 (2008
10. Barratt J, Feehally J. IgA nephropathy. J. Am. Soc. Nephrol. 16(7), 2088-2097 (2005
11. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin. Nephrol. 24(3), 179-196 (2004
12. Donadio JV and Grande JP. IgA nephropathy. N. Engl. J. Med. 347(10), 738-748 (2002
13. Maeda A, Gohda T, Funabiki K., et al. Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy. J. Clin. Lab. Anal. 17(3), 73-76 (2003
14. Kalantari S, Rutishauser D, Samavat S., et al. Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography. PLoS ONE 8(12), e80830 (2013
15. Stangou M, Papagianni A, Bantis C., et al. Up-regulation of urinary markers predict outcome in iga nephropathy but their predictive value is influenced by treatment with steroids and azathioprine. Clin. Nephrol. 80(3), 203-210 (2013
16. Liu L, Zhang Y, Duan X., et al. C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy. J. Clin. Immunol. 34(2), 224-232 (2014
17. Coppo R, Amore A, Peruzzi L, Vergano L, Camilla R. Innate immunity and IgA nephropathy. J. Nephrol. 23(6), 626-632 (2010
18. Liu LL, Jiang Y, Wang LN, and Liu N. Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy. Clin. Exp. Immunol. 169(2), 148-155 (2012
19. Surin B, Sachon E, Rougier JP., et al. LG3 fragment of endorepellin is a possible biomarker of severity in iga nephropathy. Proteomics 13(1), 142-152 (2013
20. Bakker WW, van Dael CM, Pierik LJ., et al. Altered activity of plasma hemopexin in patients with minimal change disease in relapse. Pediatr. Nephrol. 20(10), 1410-1415 (2005
21. Lundberg S, Gunnarsson I, Jacobson SH. Impact of the apolipoprotein B/apolipoprotein A-I ratio on renal outcome in immunoglobulin A nephropathy. Scand. J. Urol. Nephrol. 46(2), 148-155 (2012
22. Jackson D, Craven RA, Hutson RC., et al. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin. Cancer Res. 13(24), 7370-7379 (2007
23. Humphries JM, Penno MA, Weiland F., et al. Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer. Biochim. Biophys. Acta 1844(5), 1051-1058 (2014
24. Khositseth S, Kanitsap N, Warnnissorn N, Thongboonkerd V. IgA nephropathy associated with hodgkin's disease in children: a case report, literature review and urinary proteome analysis. Pediatr. Nephrol. 22(4), 541-546 (2007
25. Moon PG, Lee JE, You S., et al. Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy. Proteomics 11(12), 2459-2475 (2011
26. Yanagawa H, Suzuki H, Suzuki Y., et al. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS ONE 9(5), e98081 (2014
27. Suzuki Y, Matsuzaki K, Suzuki H., et al. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin. Exp. Nephrol. 18(5) 770-777 (2014
28. Meng H, Zhang L, E X., et al. Application of Oxford classification, and overexpression of transforming growth factor-beta1 and immunoglobulins in immunoglobulin A nephropathy: correlation with World Health Organization classification of immunoglobulin A nephropathy in a Chinese patient cohort. Transl Res. 163(1), 8-18 (2014
29. Hastings MC, Moldoveanu Z, Julian BA., et al. Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin. J. Am. Soc. Nephrol. 5(11), 2069-2074 (2010
30. Hastings MC, Moldoveanu Z, Suzuki H., et al. Biomarkers in iga nephropathy: relationship to pathogenetic hits. Expert Opin. Med. Diagn. 7(6), 615-627 (2013
31. Zhao N, Hou P, Lv J., et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 82(7), 790-796 (2012
32. Takahashi K, Raska M, Stuchlova Horynova M., et al. Enzymatic sialylation of IgA1 o-glycans: implications for studies of IgA nephropathy. PLoS ONE 9(2), e99026 (2014
33. Takahashi K, Smith AD, Poulsen K., et al. Naturally occurring structural isomers in serum IgA1 o-glycosylation. J. Proteome Res. 11(2), 692-702 (2012
34. Suzuki H, Raska M, Yamada K., et al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J. Biol. Chem. 289(8), 5330-5339 (2014
35. Iwatani H, Inoue T, Wada Y., et al. Quantitative change of IgA hinge O-glycan composition is a novel marker of therapeutic responses of IgA nephropathy. Biochem. Biophys. Res. Commun. 428(3), 339-342 (2012
36. Sogabe A, Uto H, Kanmura S., et al. Correlation of serum levels of complement C4a desArg with pathologically estimated severity of glomerular lesions and mesangial hypercellularity scores in patients with IgA nephropathy. Int. J. Mol. Med. 32(2), 307-314 (2013
37. Zhang J, Wang C, Tang Y., et al. Serum immunoglobulin A/C3 ratio predicts progression of immunoglobulin A nephropathy. Nephrology (Carlton) 18(2), 125-131 (2013
38. Kim SJ, Koo HM, Lim BJ., et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One 7(7), e40495 (2012
39. Zivkovic AM, Yang J, Georgi K., et al. Serum oxylipin profiles in iga nephropathy patients reflect kidney functional alterations. Metabolomics 8(6), 1102-1113 (2012
40. Delanghe SE, Speeckaert MM, Segers H., et al. Soluble transferrin receptor in urine, a new biomarker for IgA nephropathy and Henoch-Schonlein purpura nephritis. Clin. Biochem. 46(7-8), 591-597 (2013
41. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev. 18(5), 504-511 (2004
42. Ju T, Brewer K, D'Souza A, Cummings RD, Canfield WM. Cloning and expression of human core 1 beta1,3-galactosyltransferase. J. Biol. Chem. 277(1), 178-186 (2002
43. Hiki Y, Odani H, Takahashi M., et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in iga nephropathy. Kidney Int. 59(3), 1077-1085 (2001
44. Tomana M, Matousovic K, Julian BA., et al. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int. 52(2), 509-516 (1997
45. Tomana M, Novak J, Julian BA., et al. Circulating immune complexes in iga nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J. Clin. Invest. 104(1), 73-81 (1999
46. Serino G, Sallustio F, Cox SN, Pesce F, Schena FP. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in iga nephropathy. J. Am. Soc. Nephrol. 23(5), 814-824 (2012
47. Cox SN, Sallustio F, Serino G., et al. Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in iga nephropathy. Kidney Int. 78(4), 396-407 (2010
48. Tan K, Chen J, Li W., et al. Genome-wide analysis of microRNAs expression profiling in patients with primary IgA nephropathy. Genome 56(3), 161-169 (2013
49. Bao H, Chen H, Zhu X., et al. MiR-223 downregulation promotes glomerular endothelial cell activation by upregulating importin alpha4 and alpha5 in iga nephropathy. Kidney Int. 85(3), 624-635 (2014
50. Wang G, Kwan BC, Lai FM., et al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis. Markers 28(2), 79-86 (2010
51. Wang G, Kwan BC, Lai FM., et al. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis. Markers 30(4), 171-179 (2011
52. Wang G, Kwan BC, Lai FM., et al. Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. Am. J. Nephrol. 36(5), 412-418 (2012
53. Szeto CC, Ching-Ha KB, Ka-Bik L., et al. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis. Markers 33(3), 137-144 (2012
54. Suzuki H, Kiryluk K, Novak J., et al. The pathophysiology of IgA nephropathy. J. Am. Soc. Nephrol. 22(10), 1795-1803 (2011
55. Singh A, Satchell SC, Neal CR., et al. Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J. Am. Soc. Nephrol. 18(11), 2885-2893 (2007
56. Ebefors K, Granqvist A, Ingelsten M., et al. Role of glomerular proteoglycans in iga nephropathy. PLoS One 6(4), e18575 (2011
57. Villanueva S, Contreras F, Tapia A., et al. Basic fibroblast growth factor reduces functional and structural damage in chronic kidney disease. Am. J. Physiol. Renal. Physiol. 306(4), F430-F441 (2014
58. Salmivirta M, Lidholt K, Lindahl U. Heparan sulfate: a piece of information. FASEB J. 10(11), 1270-1279 (1996
59. Medical Physiology (2nd Edition). Boron WF, Boulpaep EL (Eds). Elsevier, PA, USA, 1337 (2012
60. Hill GS, Karoui KE, Karras A., et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies. Kidney Int. 79(6), 635-642 (2011
61. Lai KN, Leung JC, Chan LY., et al. Podocyte injury induced by mesangial-derived cytokines in iga nephropathy. Nephrol. Dial. Transplant. 24(1), 62-72 (2009
62. Tian J, Wang HP, Mao YY, Jin J, Chen JH. Reduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin A nephropathy. J. Int. Med. Res. 35(3), 338-345 (2007
63. Xu L, Yang HC, Hao CM., et al. Podocyte number predicts progression of proteinuria in iga nephropathy. Mod. Pathol. 23(9), 1241-1250 (2010
64. Choi SY, Suh KS, Choi DE, Lim BJ. Morphometric analysis of podocyte foot process effacement in iga nephropathy and its association with proteinuria. Ultrastruct. Pathol. 34(4), 195-198 (2010
65. Kodama F, Asanuma K, Takagi M., et al. Translocation of dendrin to the podocyte nucleus in acute glomerular injury in patients with IgA nephropathy. Nephrol. Dial. Transplant. 28(7), 1762-1772 (2013
66. Asanuma K, Campbell KN, Kim K, Faul C, Mundel P. Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytes. Proc. Natl Acad. Sci. USA 104(24), 10134-10139 (2007
67. Qiu LQ, Sinniah R, IHH S. Downregulation of Bcl-2 by podocytes is associated with progressive glomerular injury and clinical indices of poor renal prognosis in human iga nephropathy. J. Am. Soc. Nephrol. 15(1), 79-90 (2004
68. Zhou XJ, Cheng FJ, Qi YY., et al. FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy. PLoS ONE 8(4), e61208 (2013
69. Liu LL, Liu N, Chen Y., et al. Glomerular mannose-binding lectin deposition is a useful prognostic predictor in immunoglobulin A nephropathy. Clin. Exp. Immunol. 174(1), 152-160 (2013
70. Berthelot L, Papista C, Maciel TT., et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J. Exp. Med. 209(4), 793-806 (2012
71. Snoeck V, Peters IR, Cox E. The IgA system: a comparison of structure and function in different species. Vet. Res. 37(3), 455-467 (2006
72. Launay P, Grossetete B, Arcos-Fajardo M., et al. Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J. Exp. Med. 191(11), 1999-2009 (2000
73. Moura IC, Centelles MN, Arcos-Fajardo M., et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in iga nephropathy. J. Exp. Med. 194(4), 417-425 (2001
74. Moura IC, Arcos-Fajardo M, Sadaka C., et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in iga nephropathy. J. Am. Soc. Nephrol. 15(3), 622-634 (2004
75. Moura IC, Arcos-Fajardo M, Gdoura A., et al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in iga nephropathy. J. Am. Soc. Nephrol. 16(9), 2667-2676 (2005
76. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8(1), 34-47 (2008
77. Szeto CC and Li PK. MicroRNAs in iga nephropathy. Nat. Rev. Nephrol. 10(5), 249-256 (2014
78. Fang Y, Yu X, Liu Y., et al. miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-alpha activation. Am. J. Physiol. Renal. Physiol. 304(10), F1274-F1282 (2013
79. Bjornson Granqvist A, Ebefors K, Saleem MA., et al. Podocyte proteoglycan synthesis is involved in the development of nephrotic syndrome. Am. J. Physiol. Renal. Physiol. 291(4), F722-F730 (2006
80. Wang W, Qiu L, Howard A., et al. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy. J. Renin Angiotensin Aldosterone Syst. doi:10.1177/1470320313507123 (2014) (Epub ahead of print
81. Zhao S, Gu X, Groome LJ, Wang Y. Decreased nephrin and GLEPP-1, but increased VEGF, Flt-1, and nitrotyrosine, expressions in kidney tissue sections from women with preeclampsia. Reprod. Sci. 16(10), 970-979 (2009
82. Qin W, Chung AC, Huang XR., et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 22(8), 1462-1474 (2011